Albireo, An Ipsen Company
Clinical trials sponsored by Albireo, An Ipsen Company, explained in plain language.
-
New drug may help kids with rare liver disease avoid transplant
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called odevixibat in 180 children with biliary atresia, a rare liver disease. The goal is to see if the drug helps children stay alive without needing a liver transplant over the long term. Children who completed a previous study can join this open-label e…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Could this pill help kids with biliary atresia skip a liver transplant?
Disease control OngoingThis Phase 3 study tests odevixibat, a daily pill, in 254 children with biliary atresia who recently had Kasai surgery. The goal is to see if the drug can prevent the need for a liver transplant or death. Children take either odevixibat or a placebo for up to 2 years, and researc…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC